Researchers studied 178 children with migraines to find out which treatments work best and why some kids respond better than others. They compared a common heart medicine called propranolol with behavioral therapy (learning techniques to manage pain). Both treatments significantly reduced how often kids got migraines and how much the headaches interfered with their daily lives. The study found that certain factors—like whether kids had other health conditions or nutritional deficiencies—could predict who would benefit most from treatment. This suggests doctors should personalize migraine treatment for each child rather than using a one-size-fits-all approach.
The Quick Take
- What they studied: Whether propranolol (a blood pressure medicine) or behavioral therapy (learning coping skills) works better for treating migraines in children, and what signs predict which kids will improve the most.
- Who participated: 178 children diagnosed with migraines, divided into two groups based on how severe their migraines were at the start of the study.
- Key finding: Both treatments worked well. Kids taking propranolol reduced their monthly migraines from about 3-4 per month to 2 per month. Kids doing behavioral therapy reduced theirs from about 6 per month to 3 per month. Both groups also reported less disruption to school and activities.
- What it means for you: If your child has migraines, either medication or learning behavioral techniques can help—talk with your doctor about which might work best based on your child’s specific situation. The study suggests checking for other health issues and nutritional problems may help predict success.
The Research Details
This was a prospective observational study, which means researchers followed children forward in time and observed what happened with their treatments. The 178 children were divided into two groups based on how disabled they were by migraines at the beginning—one group had mild-to-moderate migraines, and the other had more severe ones. One group received propranolol (a medication that slows heart rate and reduces blood vessel constriction), while the other group received structured behavioral interventions (learning techniques like relaxation, stress management, and coping strategies). Researchers measured outcomes at 12 weeks using standardized scales that assess migraine frequency and how much migraines interfere with daily life. They also checked for other health conditions, nutritional deficiencies, and monitored how well kids stuck to their treatment plans.
This research approach is important because it reflects real-world treatment in actual clinical settings rather than artificial laboratory conditions. By following children over time and comparing two different treatment approaches, researchers could see which actually works better in practice. Identifying predictors of success helps doctors personalize treatment—instead of guessing which approach will work, they can use specific markers to choose the best option for each child.
This study has several strengths: it prospectively followed patients (stronger than looking backward), used standardized diagnostic criteria and measurement scales, monitored adherence to treatment, and evaluated both clinical and biochemical factors. However, it was a single-center study (only one location), which may limit how well results apply elsewhere. The study was retrospectively registered on ClinicalTrials.gov, which is less ideal than pre-registration. Results should be considered promising but may need confirmation in larger, multi-center studies.
What the Results Show
Both treatment groups showed substantial improvement over 12 weeks. The group receiving propranolol reduced their average monthly migraine attacks from 3.5 to 2.1 attacks per month—about a 40% reduction. The behavioral therapy group reduced their attacks from 6.4 to 3.1 per month—also about a 50% reduction. When measuring how much migraines disrupted daily life (school, sports, social activities), the propranolol group improved from a score of 8.6 to 5.75, while the behavioral therapy group improved from 24.4 to 16.1. Both improvements were statistically significant, meaning they weren’t due to chance. Importantly, both groups showed comparable proportional improvements, suggesting that either approach can be effective depending on the individual child.
The study identified several factors that predicted better treatment outcomes. Children without other health conditions (comorbidities) responded better than those with additional health issues. Nutritional status mattered too—children without vitamin or mineral deficiencies had better outcomes. Adherence to treatment (actually taking medication or attending behavioral sessions) was crucial; kids who stuck with their treatment plan improved more. These findings suggest that a comprehensive approach addressing overall health, not just migraines alone, produces better results.
This research aligns with existing evidence showing propranolol is effective for pediatric migraine prevention. It also supports growing research suggesting behavioral interventions are valuable for migraine management in children. The finding that both approaches work comparably well is important because it gives families options—some children or families may prefer behavioral approaches to avoid medication, while others may prefer medication. The emphasis on personalized treatment based on individual factors reflects current trends in precision medicine.
The study was conducted at a single medical center, so results may not apply equally to all populations or settings. The study was retrospectively registered, which is less rigorous than pre-registration. The abstract doesn’t clearly specify all inclusion/exclusion criteria or provide complete demographic information. The 12-week timeframe is relatively short; longer follow-up would show whether benefits persist. The study doesn’t clearly explain how children were assigned to groups, which could affect result interpretation. Results should be considered preliminary and may need confirmation in larger, multi-center studies with longer follow-up periods.
The Bottom Line
For children with migraines: (1) Propranolol is an effective preventive medication option—moderate confidence based on this study. (2) Behavioral therapy (stress management, relaxation techniques, coping skills) is also effective—moderate confidence. (3) A personalized approach considering the child’s overall health, nutritional status, and family preferences is recommended—moderate confidence. (4) Screen for other health conditions and nutritional deficiencies before or during treatment—moderate confidence. These recommendations should be discussed with your child’s doctor.
This research is relevant for: children and teens with recurring migraines, parents seeking treatment options, pediatricians and neurologists treating migraines in children. It may be less relevant for adults with migraines (though some principles may apply) or children with other types of headaches. This research should not replace personalized medical advice from your child’s healthcare provider.
Based on this study, expect to see meaningful improvement within 12 weeks of starting either treatment. Most children showed noticeable reduction in migraine frequency and impact on daily life by this timeframe. However, individual responses vary—some children may improve faster, others slower. Consistent adherence to treatment (taking medication regularly or attending behavioral sessions) appears crucial for success.
Want to Apply This Research?
- Track migraine frequency weekly: record the number of migraine days per week and rate severity (1-10 scale). Also track how much migraines interfered with school, sports, or social activities that day. This creates a clear picture of improvement over 4-12 weeks.
- If using behavioral therapy: practice one relaxation technique daily (deep breathing, progressive muscle relaxation, or guided imagery). Set phone reminders for stress management breaks during high-stress times. If taking propranolol: set daily medication reminders and track adherence. Log any side effects to discuss with your doctor.
- Establish a baseline by tracking migraines for 1-2 weeks before starting treatment. Then track weekly for the first 12 weeks to see if improvement matches the study results. Continue monthly tracking after 12 weeks to ensure benefits persist. Share tracked data with your healthcare provider at follow-up appointments to adjust treatment if needed.
This research summary is for educational purposes and should not replace professional medical advice. Migraine treatment decisions for children should be made in consultation with a qualified healthcare provider (pediatrician or neurologist) who can evaluate your child’s individual health status, medical history, and specific needs. Do not start, stop, or change any migraine medications without medical supervision. While this study suggests both propranolol and behavioral therapy are effective, individual responses vary significantly. Some children may experience side effects from propranolol or may not respond to behavioral interventions. This study was conducted at a single center and results may not apply universally to all children with migraines.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.